NBP in Adult Patients With Acute Ischemic Stroke (AIS)

ClinicalTrials.gov ID: NCT02905565

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02905565. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Add-On to Standard Of-Care Study of n Butylphthalide (NBP) Softgel Capsules for Treatment of Mild to Moderate Acute Ischemic Stroke (AIS) in Adult Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on to standard of care study of NBP softgel capsules for the treatment of mild to moderate AIS in adults.

Study identification

NCT ID: NCT02905565
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: CSPC-NBP Pharmaceutical Co., Ltd.; Industry
Enrollment: 177 participants

Conditions and interventions

Conditions

Interventions

NBP Softgel Capsules Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2018 (Actual)
Primary completion: Aug 7, 2020 (Actual)
Completion: Aug 7, 2020 (Actual)
Last update posted: Sep 17, 2020

2018 – 2020

United States locations

U.S. sites: 21
U.S. states: 16
U.S. cities: 18

Facility	City	State	ZIP	Site status
Investigative Site	Los Angeles	California	90027	—
Investigative Site	Los Angeles	California	90095	—
Investigative Site	Jacksonville	Florida	32209	—
Investigative Site	Des Moines	Iowa	50314	—
Investigative Site	Louisville	Kentucky	40202	—
Investigative Site	Boston	Massachusetts	02111	—
Investigative Site	Golden Valley	Minnesota	55422	—
Investigative Site	St Louis	Missouri	63110	—
Investigative Site	Omaha	Nebraska	68123	—
Investigative Site	Buffalo	New York	14202	—
Investigative Site	Asheville	North Carolina	28801	—
Investigative Site	Columbus	Ohio	43210	—
Investigative Site	Hillsboro	Oregon	97123	—
Investigative Site	Portland	Oregon	97213	—
Investigative Site	Portland	Oregon	97225	—
Investigative Site	Portland	Oregon	97239	—
Investigative Site	Philadelphia	Pennsylvania	19104	—
Investigative Site	Charleston	South Carolina	29425	—
Investigative Site	Columbia	South Carolina	29203	—
Investigative Site	Chattanooga	Tennessee	37403	—
Investigative Site	Burlington	Vermont	05401	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02905565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 17, 2020 · Synced Nov 13, 2026